Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytosorbents (CTSO) Gross Profit (2016 - 2025)

Historic Gross Profit for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to $6.7 million.

  • Cytosorbents' Gross Profit rose 2682.65% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.2 million, marking a year-over-year increase of 934.56%. This contributed to the annual value of $25.1 million for FY2024, which is 1445.23% up from last year.
  • As of Q3 2025, Cytosorbents' Gross Profit stood at $6.7 million, which was up 2682.65% from $6.8 million recorded in Q2 2025.
  • Over the past 5 years, Cytosorbents' Gross Profit peaked at $9.3 million during Q2 2021, and registered a low of $3.6 million during Q3 2022.
  • Moreover, its 5-year median value for Gross Profit was $6.4 million (2022), whereas its average is $6.3 million.
  • Its Gross Profit has fluctuated over the past 5 years, first plummeted by 5042.97% in 2022, then soared by 5499.81% in 2023.
  • Quarter analysis of 5 years shows Cytosorbents' Gross Profit stood at $7.7 million in 2021, then dropped by 24.84% to $5.8 million in 2022, then decreased by 7.74% to $5.3 million in 2023, then increased by 22.27% to $6.5 million in 2024, then increased by 2.65% to $6.7 million in 2025.
  • Its Gross Profit was $6.7 million in Q3 2025, compared to $6.8 million in Q2 2025 and $6.2 million in Q1 2025.